.jpg "Chandni Valiathan, PhD photo")
Director Modeling and Decision Sciences
Janssen Research & Development, LLC
San Diego, California, United States
Chandni Valiathan, PhD, Director of Modeling and Decision Sciences, is the head of the Model-Based Meta-Analysis (MBMA) group at Janssen R&D and is leading the strategic integration of published clinical trial data for decision-making within the entire Janssen R&D portfolio. Prior to Janssen, while at GSK, she initiated and led the High Dimensional Data Enhanced Modeling (HiDEM) initiative to leverage novel methods to integrate clinical biomarker data into pharmacometrics modeling to drive development decisions. Dr. Valiathan has also previously established a data and analytics consulting company that helped biotech startups with data and analytics strategy, analytics software development, content creation and VC interactions. During her past tenure at Merck, Dr. Valiathan made key contributions to the development of Keytruda, including selection of the first approved clinical dose using translational modeling, and benchmarking clinical trial results using literature data. Her broad range of experience includes strategic model development for early and late clinical development, as well as multiple disease areas. She is a strong believer in innovative ways for data-informed strategic planning and decision making. Chandni has a PhD in Computational and Systems Biology from MIT and a BSc in Computer Science and Mathematics from Brandeis University.